The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

CHEMBL210602     3-[2-[(4-methylphenyl)amino]- 5-nitro...

Synonyms: BM-573, SureCN3393325, CHEBI:449741, NSC-732094, AC1NSM3C, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of BM-573

  • These data suggest that BM-573 could be useful for the prevention of myocardial infarction [1].
  • Among the BM-573-treated group, four pigs did not develop coronary artery thrombus and their myocardium appeared healthy [1].
  • The aim of this study was to evaluate the effect of BM-573 [N-terbutyl-N'-[2-(4'-methylphenylamino)-5-nitro-benzenesulfonyl]urea], a dual thromboxane A2 synthase inhibitor and receptor antagonist, on the hemodynamic response to acute pulmonary embolism [2].
  • In conclusion, dual TXA2 synthase inhibitor and receptor antagonists such as BM-573 have potential therapeutic applications, improving right ventricular efficiency and arterial oxygenation in endotoxic shock [3].
  • Moreover, BM-573 significantly decreased early atherogenesis and prevented progression of established atherosclerotic lesions [4].

High impact information on BM-573


Chemical compound and disease context of BM-573


Biological context of BM-573


Anatomical context of BM-573


Associations of BM-573 with other chemical compounds


Gene context of BM-573

  • Histological examination and immunohistochemical identification of desmin revealed necrosis in the anteroseptal region similar in both groups, while myocardial ATP dosages and electron microscopy also showed that BM-573 had no cardioprotective effect [10].

Analytical, diagnostic and therapeutic context of BM-573


  1. BM-573, a dual thromboxane synthase inhibitor and thromboxane receptor antagonist, prevents pig myocardial infarction induced by coronary thrombosis. Rolin, S., Petein, M., Tchana-Sato, V., Dogne, J.M., Benoit, P., Lambermont, B., Ghuysen, A., Kolh, P., Masereel, B. J. Pharmacol. Exp. Ther. (2003) [Pubmed]
  2. Effect of BM-573 [N-terbutyl-N'-[2-(4'-methylphenylamino)-5-nitro-benzenesulfonyl]urea], a dual thromboxane synthase inhibitor and thromboxane receptor antagonist, in a porcine model of acute pulmonary embolism. Ghuysen, A., Lambermont, B., Dogné, J.M., Kolh, P., Tchana-Sato, V., Morimont, P., Magis, D., Hanson, J., Segers, P., D'Orio, V. J. Pharmacol. Exp. Ther. (2004) [Pubmed]
  3. Effect of a novel thromboxane A2 inhibitor on right ventricular-arterial coupling in endotoxic shock. Lambermont, B., Kolh, P., Ghuysen, A., Segers, P., Dogné, J.M., Tchana-Sato, V., Morimont, P., Benoit, P., Gérard, P., Masereel, B., D'Orio, V. Shock (2004) [Pubmed]
  4. A novel thromboxane receptor antagonist and synthase inhibitor, BM-573, reduces development and progression of atherosclerosis in LDL receptor deficient mice. Cyrus, T., Yao, Y., Ding, T., Dogné, J.M., Praticò, D. Eur. J. Pharmacol. (2007) [Pubmed]
  5. Evaluation of original dual thromboxane A2 modulators as antiangiogenic agents. de Leval, X., Dassesse, T., Dogné, J.M., Waltregny, D., Bellahcène, A., Benoit, V., Pirotte, B., Castronovo, V. J. Pharmacol. Exp. Ther. (2006) [Pubmed]
  6. Pharmacological characterization of N-tert-butyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea (BM-573), a novel thromboxane A2 receptor antagonist and thromboxane synthase inhibitor in a rat model of arterial thrombosis and its effects on bleeding time. Dogné, J.M., Hanson, J., de Leval, X., Kolh, P., Tchana-Sato, V., de Leval, L., Rolin, S., Ghuysen, A., Segers, P., Lambermont, B., Masereel, B., Pirotte, B. J. Pharmacol. Exp. Ther. (2004) [Pubmed]
  7. Pharmacological profile and therapeutic potential of BM-573, a combined thromboxane receptor antagonist and synthase inhibitor. Ghuysen, A., Dogné, J.M., Chiap, P., Rolin, S., Masereel, B., Lambermont, B., Kolh, P., Tchana-Sato, V., Hanson, J., D'Orio, V. Cardiovascular drug reviews. (2005) [Pubmed]
  8. Effects of BM-573, a thromboxane A2 modulator on systemic hemodynamics perturbations induced by U-46619 in the pig. Tchana-Sato, V., Dogné, J.M., Lambermont, B., Ghuysen, A., Magis, D., Morimont, P., Hanson, J., D'Orio, V., Limet, R., Kolh, P. Prostaglandins Other Lipid Mediat. (2005) [Pubmed]
  9. Activity of a novel dual thromboxane A(2)receptor antagonist and thromboxane synthase inhibitor (BM-573) on platelet function and isolated smooth muscles. Rolin, S., Dogné, J.M., Michaux, C., Delarge, J., Masereel, B. Prostaglandins Leukot. Essent. Fatty Acids (2001) [Pubmed]
  10. Evaluation of BM-573, a novel TXA2 synthase inhibitor and receptor antagonist, in a porcine model of myocardial ischemia-reperfusion. Kolh, P., Rolin, S., Tchana-Sato, V., Pétein, M., Ghuysen, A., Lambermont, B., Hanson, J., Magis, D., Segers, P., Masereel, B., D'Orio, V., Dogne, J.M. Prostaglandins Other Lipid Mediat. (2006) [Pubmed]
WikiGenes - Universities